PARIS--(BUSINESS WIRE)--Regulatory News:
ABIVAX (Euronext Paris: FR0012333284 – ABVX) (Paris:ABVX), an emerging leader in developing and commercializing anti-viral therapies and immunotherapeutics for infectious diseases like HIV/AIDS and chronic hepatitis B (CHB), today announced that its Combined Annual General Meeting (AGM) will be held on Friday, June 24, 2016 at 10:00 AM at the company’s corporate headquarters, 5 rue de la Baume, 75008 Paris.
Advance notice of the AGM, including the meeting agenda and the proposed resolutions, was published in the BALO (French Bulletin of Obligatory Legal Announcements) on May 18, 2016. The supporting documents to the AGM are available on the company's website (www.abivax.com).
ABIVAX is an emerging global leader in the discovery, development and commercialization of anti-viral therapeutics and immunotherapeutics to treat some of the world’s most life-threatening infectious diseases, including HIV/AIDS and chronic Hepatitis B. ABIVAX has 2 compounds in clinical stage research: ABX464 a novel first-in-class resistance-proof oral small molecule HIV/AIDS therapy; and, ABX203, an immunotherapy recently approved in Cuba and in late-stage clinical development in other countries that could cure chronic Hepatitis B. ABIVAX also is advancing additional anti-viral compounds and immunotherapeutics that may enter the clinical stage in the coming 18 months. A recently updated corporate presentation, which includes a timeline for the company’s anticipated news flow, is available at www.abivax.com.
Follow us on Twitter @ABIVAX